Wyndham Wilson is an Oncologist in Bethesda, Maryland. Dr. Wilson is rated as a Distinguished provider by MediFind in the treatment of Primary Mediastinal B-Cell Lymphoma (PMBCL). His top areas of expertise are B-Cell Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and Burkitt Lymphoma.

Christopher Melani is a primary care provider, practicing in Internal Medicine in Baltimore, Maryland. Dr. Melani is rated as a Distinguished provider by MediFind in the treatment of Primary Mediastinal B-Cell Lymphoma (PMBCL). His top areas of expertise are Lymphomatoid Granulomatosis, Primary Mediastinal B-Cell Lymphoma (PMBCL), B-Cell Lymphoma, and Non-Hodgkin Lymphoma.

Edward Lee, M.D. was named one of Baltimore’s “Top Doc’s” by Baltimore Magazine in 2000 and 2002. After receiving additional training in Hematology and Medical Oncology at the University of Maryland in 1984, he remained on faculty until 1997. During his academic career, Dr. Lee was chairman of the training program for five years, started the Bone Marrow Transplant Program at the University of Maryland in 1993, and wrote 50 original articles on leukemia, lymphoma and related diseases. In 1997, Dr. Lee entered private practice as Chief of Hematology and Medical Oncology at Sinai Hospital. Practicing in Columbia since 2001, Dr. Lee treats patients with all forms of cancer, maintaining a particular interest in breast cancer, leukemia, and lymphomas. Learn more at marylandoncology.com. Dr. Lee is rated as an Experienced provider by MediFind in the treatment of Primary Mediastinal B-Cell Lymphoma (PMBCL). His top areas of expertise are Polycythemia Vera, Paget Disease of the Breast, Breast Cancer, and Primary Lymphoma of the Brain.

Dr. Nina Wagner-Johnston is Professor of Oncology at the Johns Hopkins University School of Medicine. Her areas of clinical expertise include non-Hodgkin lymphoma, Hodgkin lymphoma, and HIV-related lymphomas. Dr. Wagner-Johnston serves as the Director for the Lymphoma Drug Development Program at the Johns Hopkins University. Dr. Wagner-Johnston received her baccalaureate degree in nursing from Georgetown University in Washington, DC. She earned her MD and completed her residency training at the University of Chicago, Chicago Illinois. She performed a fellowship in Medical Oncology at Johns Hopkins University, Baltimore, Maryland. Dr. Wagner-Johnston joined the Johns Hopkins faculty in 2015. Prior to joining Johns Hopkins, Dr. Wagner-Johnston was an Assistant Professor at Washington University, St. Louis, Missouri. Her research interests include clinical trial and biomarker development for patients with lymphoma. She is additionally involved in palliative/supportive care research and has a particular interest in chemotherapy-induced peripheral neuropathy. Dr. Wagner-Johnston serves as a member on the NCCN Cancer Related Fatigue Guidelines Panel and the ASCO Neuropathy Guidelines Panel. She has served as a journal reviewer for Annals of Oncology, Leukemia and Lymphoma, Blood, and the Journal of Nuclear Medicine. She is a previous recipient of a Young Investigator Award at the Supportive Oncology Conference as well as a Mentoring Program Award through the American Academy of Hospice and Palliative Medicine. She has served on the National Cancer Institute (NCI) Lymphoma Steering Committee Clinical Trials Design Committee and the NCI Symptom Management and Health Related Quality of Life Steering Committee. She is a member of the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), the AIDS Malignancies Consortium (AMC), and the Eastern Cancer Oncology Group (ECOG) Lymphoma Committee. Dr. Wagner is rated as an Experienced provider by MediFind in the treatment of Primary Mediastinal B-Cell Lymphoma (PMBCL). Her top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Richard J. Jones, M.D., is a Professor of Oncology and Medicine, Director of the Bone Marrow Transplantation Program, and Co-Director of the Hematologic Malignancies Program at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Dr. Jones received his Bachelor of Science in chemistry from Bucknell University prior to completing his medical degree at the Temple University School of Medicine. He then completed his residency at Temple University Hospital, where he was appointed to serve as Chief Resident in Internal Medicine. Dr. Jones later came to Johns Hopkins to complete his Medical Oncology Fellowship, and was then recruited to the faculty. Dr. Jones’ research is aimed at better understanding the biology of normal and cancer stem cells, with the goal of translating promising findings to the clinic particularly in the area of blood and marrow transplantation (BMT). Dr. Jones' laboratory discovered one the most commonly-used stem cell markers, Aldefluor which identifies cells based on their expression of aldehyde dehydrogenase 1 (ALDH1), and have used this marker to identify and characterize normal stem cells and cancer stem cells from many hematologic malignancies. This work also led to the development of post-transplant cyclophosphamide and effective related haploidentical BMT. Cyclophosphamide is metabolized by ALDH1, which is the reason both stem cells and memory lymphocytes are resistant to the drug. Recently, Dr. Jones' laboratory found that cytochrome P450 enzymes are a major mechanism by which the bone marrow stem cell niche protects both normal and leukemia stem cells. Dr. Jones co-leads the Hematologic Malignancies and Bone Marrow Transplantation Research Program. In addition to his promising work in the laboratory, Dr. Jones is recognized as a gifted mentor. During his tenure at Hopkins, he has trained a generation of leading physician-scientists who have excelled at Johns Hopkins and across the country. Dr. Jones has also authored numerous peer-reviewed articles that have been published in such prestigious journals as Blood, Nature, the New England Journal of Medicine, Lancet, PNAS, the Annals of Internal Medicine, the Journal of Clinical Oncology, the Journal of the National Cancer Institute, the British Journal of Haematology, and Leukemia. Dr. Jones is rated as an Experienced provider by MediFind in the treatment of Primary Mediastinal B-Cell Lymphoma (PMBCL). His top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Non-Hodgkin Lymphoma, Leukemia, and Splenectomy.

Richard F. Ambinder, M.D., Ph.D., currently serves as the James B. Murphy Professor of Oncology and the Director of the Division of Hematologic Malignancies at the Johns Hopkins Kimmel Cancer Center. He is program co-leader of the Hematologic Malignancies and Bone Marrow Transplantation Program and leads the AIDS Malignancy Consortium (AMC) site at Johns Hopkins and the AMC Translational Sciences Working Group nationally. Dr. Ambinder graduated from Harvard College with a Bachelor’s degree in biochemistry, after which he received his medical degree from the Johns Hopkins University School of Medicine before completing his residency at the Johns Hopkins Hospital. He also earned his Ph.D. in pharmacology from the Johns Hopkins University, and completed his oncology fellowship at Johns Hopkins. Within the clinic, Dr. Ambinder is active in the treatment of lymphoma and Kaposi’s sarcoma. Dr. Ambinder’s research is focused on exploring opportunities to prevent or treat cancer with viral infections. Virus-associated tumors are among the most common malignancies in certain populations and regions. For instance, Burkitt's lymphoma (EBV) and Kaposi's sarcoma (KSHV) are common in equatorial Africa, nasopharyngeal carcinoma (EBV) is common in southern Chinese populations or those with southern Chinese origins, and immunoblastic lymphomas (EBV) are common in immunocompromised patients (organ transplant recipients, AIDS patients, etc). Thus, Dr. Ambinder’s new approaches to prevention, diagnosis, and treatment stand to have a direct impact on the lives of cancer patients around the globe. Additionally, the study of how viruses can impact these tumors is important in creating model systems for the development of new approaches to cancer care. Currently, many immunotherapies target unidentified antigens, making the measurement of relevant immune responses problematic at best. However, in EBV-associated tumors the antigens are well defined, thus allowing the Ambinder lab to define the epitope-specific cellular immune responses. As a result of this breakthrough, interventions designed to alter immune response —whether they be vaccine based interventions, adoptive immunotherapy interventions, or pharmacologic interventions — may all be assessed in terms of relevant surrogate markers. Much in the same way the treatment of Hodgkin's lymphoma with radiotherapy and chemotherapy paved the way for the modern approach to cancer treatment more broadly, the treatment of EBV-associated tumors (including Hodgkin's lymphoma) may pave the way to the more generalized use of these modalities to treat a myriad of cancer types. Dr. Ambinder is rated as an Experienced provider by MediFind in the treatment of Primary Mediastinal B-Cell Lymphoma (PMBCL). His top areas of expertise are Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Tissue Biopsy, and Bone Marrow Aspiration.

Dr. Lode J. Swinnen is a cancer specialist in Baltimore caring for patients with lymphoma. Dr. Swinnen received his M.B.Ch.B. degree from the University of Cape Town Medical School. He completed his residency at Presence Saint Joseph Hospital and performed a fellowship in hematology-oncology at Loyola University Stritch School of Medicine. Dr. Swinnen joined the Johns Hopkins faculty in 2002. His research interests include lymphomas and immunodeficiency-associated malignancies. Dr. Swinnen is a member of the Eastern Cooperative Oncology Group and the National Comprehensive Cancer Network. Dr. Swinnen is rated as an Experienced provider by MediFind in the treatment of Primary Mediastinal B-Cell Lymphoma (PMBCL). His top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma, Small Lymphocytic Lymphoma (SLL), and Bone Marrow Transplant.

As an active participant in the medical community, Mohit Narang, M.D. has served as a primary investigator and research assistant on many trials. During Dr. Narang’s fellowship, he was honored with the invitation to attend the Masterclass in Clinical Oncology at Montecatini, Italy by the European School of Oncology. He holds professional memberships with the American Society of Clinical Oncology, American Society of Hematology, as well as the European Society of Medical Oncology. Learn more at marylandoncology.com. Dr. Narang is rated as an Experienced provider by MediFind in the treatment of Primary Mediastinal B-Cell Lymphoma (PMBCL). His top areas of expertise are Multiple Myeloma, Agranulocytosis, Paget Disease of the Breast, Thrombocytopenia, and Bone Marrow Transplant.

Andrew Mener, M.D. has experience treating a wide range of adult hematologic and oncologic disorders, with a particular interest in treating breast, lung, gastrointestinal and hematologic malignancies. He takes great pride in delivering personalized, compassionate care and strives to effectively explain complex treatment options to his patients. He strongly believes in the importance of treating each and every patient as an individual. Learn more at marylandoncology.com. Dr. Mener is rated as an Experienced provider by MediFind in the treatment of Primary Mediastinal B-Cell Lymphoma (PMBCL). His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Iron Deficiency Anemia, and Severe Congenital Neutropenia.

Dr. James Xu received a bachelor of science in chemical engineering with a minor in mathematics from Brigham Young University and his medical degree from University of Minnesota. He completed his internal medicine residency at the Yale-New Haven Hospital of Yale University in New Haven, CT, and his hematology and medical oncology fellowship at the New York-Presbyterian Hospital of Columbia University in New York City. Because of his unique background in engineering and medicine, Dr. Xu was the recipient of the American Society of Clinical Oncology-Conquer Cancer Foundation Young Investigator Award in 2011 and Merit Award in 2012. Dr. Xu is a strong advocate of precision medicine and he is the first person to have proposed and preliminarily confirmed the feasibility of using deep sequencing technology to detect genetic mutation in rare cell samples such as circulating tumor cells from cancer patients’ peripheral blood. He has published in peer-reviewed journals in lung, breast, and pancreatic cancers. Dr. Xu is rated as an Experienced provider by MediFind in the treatment of Primary Mediastinal B-Cell Lymphoma (PMBCL). His top areas of expertise are Pulmonary Embolism, Deep Vein Thrombosis, Protein S Deficiency, and Congenital Antithrombin 3 Deficiency.

Najeff Waseem is a Hematologist and a Hematologist Oncology provider in Columbia, Maryland. Dr. Waseem has been practicing medicine for over 10 years and is rated as an Experienced provider by MediFind in the treatment of Primary Mediastinal B-Cell Lymphoma (PMBCL). His top areas of expertise are Thrombocytopenia, Agranulocytosis, Chronic Familial Neutropenia, and Triple-Negative Breast Cancer.

Sunil Gupta is a primary care provider, practicing in Internal Medicine in Cumberland, Maryland. Dr. Gupta is rated as an Experienced provider by MediFind in the treatment of Primary Mediastinal B-Cell Lymphoma (PMBCL). His top areas of expertise are Hypertension, Familial Hypertension, Glucocorticoid-Remediable Aldosteronism, Craniectomy, and Extracranial-Intracranial Bypass Surgery. Dr. Gupta is currently accepting new patients.

"Dr. Ari D. Fishman is a hematologist affiliated with Sibley Memorial Hospital, Holy Cross Hospital and George Washington University Hospital, where he serves as an assistant professor of medicine for the School of Medicine. He practices out of Maryland Oncology and Hematology, located in Wheaton, Maryland and Silver Spring, Maryland. Dr. Fishman earned his medical degree from Sackler School of Medicine. He completed a residency in internal medicine at the Beth Israel Medical Center, followed by a fellowship in hematology and oncology at the Montefiore Medical Center. Dr. Fishman previously worked at Washington Oncology Hematology Center, located in Washington, D.C. and Chevy Chase, Maryland. Dr. Fishman has been named a Top Doctor in Hematology and Oncology by Washingtonian Magazine and a Top Doctor by Consumers’ Checkbook magazine. Dr. Fishman is a member of the American College of Physicians and the American Society of Clinical Oncology. Dr. Fishman has contributed to numerous publications. Selected Publications Fishman AD, Hoffman A, Volterra F, Frymus M, Gentilluci M. ""Intracaval and intracardiac metastatic nonseminomatous germ cell tumor: a rare cause of hemolytic anemia and thrombocytopenia."" Cancer Invest. 2002;20(7-8):996-1001.". Dr. Fishman is rated as an Experienced provider by MediFind in the treatment of Primary Mediastinal B-Cell Lymphoma (PMBCL). His top areas of expertise are Schnitzler Syndrome, Monoclonal Gammopathy of Undetermined Significance (MGUS), Myelodysplastic Syndrome (MDS), and Childhood Iron Deficiency Anemia.

Victor Priego is a Hematologist Oncology specialist and an Oncologist in Bethesda, Maryland. Dr. Priego is rated as an Experienced provider by MediFind in the treatment of Primary Mediastinal B-Cell Lymphoma (PMBCL). His top areas of expertise are Myelodysplastic Syndrome (MDS), Anemia, Hemangioma Thrombocytopenia Syndrome, Thrombocytopenia, and Splenectomy.

Joseph Cinderella is a Cardiologist in Salisbury, Maryland. Dr. Cinderella is rated as an Experienced provider by MediFind in the treatment of Primary Mediastinal B-Cell Lymphoma (PMBCL). His top areas of expertise are Aortic Valve Stenosis, Angina, Coronary Heart Disease, Transcatheter Aortic Valve Replacement (TAVR), and Aortic Valve Replacement.

Clara Chen is a Nuclear Medicine provider in Bethesda, Maryland. Dr. Chen is rated as an Advanced provider by MediFind in the treatment of Primary Mediastinal B-Cell Lymphoma (PMBCL). Her top area of expertise is Primary Mediastinal B-Cell Lymphoma (PMBCL).

Nancy Hardy is an Oncologist and a Transplant Surgeon in Baltimore, Maryland. Dr. Hardy is rated as an Advanced provider by MediFind in the treatment of Primary Mediastinal B-Cell Lymphoma (PMBCL). Her top areas of expertise are Acute Myeloid Leukemia (AML), Multiple Myeloma, Acute Myeloblastic Leukemia without Maturation, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Hardy is currently accepting new patients.

Lillian Man is a Hematologist Oncology specialist and a Hematologist in Bel Air, Maryland. Dr. Man is rated as an Advanced provider by MediFind in the treatment of Primary Mediastinal B-Cell Lymphoma (PMBCL). Her top areas of expertise are Familial Colorectal Cancer, Chronic Lymphocytic Leukemia (CLL), Paget Disease of the Breast, and Breast Cancer. Dr. Man is currently accepting new patients.

James Kochenderfer is a Hematologist in Bethesda, Maryland. Dr. Kochenderfer is rated as an Experienced provider by MediFind in the treatment of Primary Mediastinal B-Cell Lymphoma (PMBCL). His top areas of expertise are Multiple Myeloma, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Transplant.

Susan Hodges is a Nurse Practitioner in Baltimore, Maryland. Ms. Hodges is rated as an Experienced provider by MediFind in the treatment of Primary Mediastinal B-Cell Lymphoma (PMBCL). Her top areas of expertise are Smoldering Multiple Myeloma, Primary Mediastinal B-Cell Lymphoma (PMBCL), Classical Hodgkin Lymphoma, and Chronic Graft Versus Host Disease (cGvHD). Ms. Hodges is currently accepting new patients.